




PHARMACEUTICAL 2023

Sonoma Pharmaceuticals Inc.
Rank 239 of 446





RealRate

PHARMACEUTICAL 2023

Sonoma Pharmaceuticals Inc. Rank 239 of 446



The relative strengths and weaknesses of Sonoma Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sonoma Pharmaceuticals Inc. compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 61% points. The greatest weakness of Sonoma Pharmaceuticals Inc. is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 53% points.

The company's Economic Capital Ratio, given in the ranking table, is 69%, being 26% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	16,430
Cost of Goods Sold	8,635
Intangible Assets	0
Liabilities, Current	5,819
Liabilities, Non-Current	309
Other Assets	2,095
Other Compr. Net Income	267
Other Expenses	-332
Other Liabilities	4,020
Other Net Income	469
Other Revenues	12,628
Property and Equipment	320
Research and Development	125
Selling, General and Administrative Expense	9,755

Output Variable	Value in 1000 USD
Assets	18,845
Liabilities	10,148
Expenses	18,183
Revenues	12,628
Stockholders Equity	8,697
Net Income	-5,086
Comprehensive Net Income	-4,952
Economic Capital Ratio	69%